PMID- 28413172
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20180326
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 64
IP  - 5
DP  - 2017 May 30
TI  - The effects of metformin on fibroblast growth factor 19, 21 and fibroblast growth 
      factor receptor 1 in high-fat diet and streptozotocin induced diabetic rats.
PG  - 543-552
LID - 10.1507/endocrj.EJ16-0391 [doi]
AB  - To understand metformin's effects on fibroblast growth factors (FGFs) and 
      fibroblast growth factor receptor 1 (FGFR1), we investigated circulating 
      fibroblast growth factor-19 (FGF19), FGF21 levels, and FGFR1 in type 2 diabetes 
      mellitus (T2DM). In addition, protein kinase B (Akt) signaling pathway was 
      detected to explain the possible mechanisms. T2DM was induced by feeding rats 
      with high-fat diet for 11 weeks, followed by a low dose of streptozotocin (STZ, 
      30-35 mg/kg, intraperitoneally). Control rats (Con) were fed on a normal chow; 
      diabetic rats (DM) were fed on high-fat diet supplemented with or without 
      metformin (METF) for 12 weeks (500 mg.kg(-1).d(-1)). Biochemical parameters were 
      detected at the end of 24th weeks. FGFR1 expression and protein kinase B (Akt) 
      phosphorylation in the pancreas and visceral adipose tissues were detected using 
      either Western blot (WB) or immunohistochemistry (IHC). Serum FGF19 and FGF21 
      were measured using enzyme-linked immune sorbent assay (ELISA). Metformin treated 
      DM rats showed improved glucose, lipid and bile acid metabolism. Besides, 
      significantly decreased FGF19 and increased FGF21 were observed in DM+METF rats. 
      DM rats showed significantly increased FGFR1 both in the pancreas and visceral 
      adipose tissues. While in DM+METF rats, FGFR1 was almost remained at a normal 
      level in the pancreas and increased in the visceral adipose tissue compared to 
      that in DM rats. Besides, metformin treatment restores Akt phosphorylation in 
      both tissues. The altered glucose and lipid profiles by metformin treatment may 
      be associated with the increased circulating FGF21 and tissue-specific 
      expressions of FGFR1.
FAU - Wang, Yan
AU  - Wang Y
AD  - School of Medicine, Shandong University, Jinan 250013, Shandong Province, China.
AD  - Department of Endocrinology, Jinan Central Hospital Affiliated to Shandong 
      University, Jinan 250013, Shandong Province, China.
FAU - Dang, Ningning
AU  - Dang N
AD  - Department of Dermatology, Jinan Central Hospital Affiliated to Shandong 
      University, Jinan 250013, Shandong Province, China.
FAU - Sun, Pei
AU  - Sun P
AD  - Department of Endocrinology, Jinan Central Hospital Affiliated to Shandong 
      University, Jinan 250013, Shandong Province, China.
FAU - Xia, Jin
AU  - Xia J
AD  - Department of Endocrinology, Jinan Central Hospital Affiliated to Shandong 
      University, Jinan 250013, Shandong Province, China.
AD  - Department of Medicine, Taishan Medical University, Taian 271000, Shandong 
      Province, China.
FAU - Zhang, Chunxue
AU  - Zhang C
AD  - Department of Endocrinology, Jinan Central Hospital Affiliated to Shandong 
      University, Jinan 250013, Shandong Province, China.
AD  - Department of Medicine, Taishan Medical University, Taian 271000, Shandong 
      Province, China.
FAU - Pang, Shuguang
AU  - Pang S
AD  - School of Medicine, Shandong University, Jinan 250013, Shandong Province, China.
AD  - Department of Endocrinology, Jinan Central Hospital Affiliated to Shandong 
      University, Jinan 250013, Shandong Province, China.
AD  - Department of Medicine, Taishan Medical University, Taian 271000, Shandong 
      Province, China.
LA  - eng
PT  - Journal Article
DEP - 20170411
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (fibroblast growth factor 21)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - 9100L32L2N (Metformin)
RN  - EC 2.7.10.1 (Fgfr1 protein, rat)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Experimental/blood/*drug therapy
MH  - Diet, High-Fat
MH  - Fibroblast Growth Factors/*blood
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Intra-Abdominal Fat/drug effects/metabolism
MH  - Male
MH  - Metformin/pharmacology/*therapeutic use
MH  - Pancreas/drug effects/metabolism
MH  - Phosphorylation/drug effects
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Fibroblast Growth Factor, Type 1/*metabolism
MH  - Signal Transduction/drug effects
OTO - NOTNLM
OT  - Diabetes
OT  - FGF21
OT  - FGFR1
OT  - Visceral adipose
OT  - beta cell
EDAT- 2017/04/18 06:00
MHDA- 2018/03/27 06:00
CRDT- 2017/04/18 06:00
PHST- 2017/04/18 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
PHST- 2017/04/18 06:00 [entrez]
AID - 10.1507/endocrj.EJ16-0391 [doi]
PST - ppublish
SO  - Endocr J. 2017 May 30;64(5):543-552. doi: 10.1507/endocrj.EJ16-0391. Epub 2017 
      Apr 11.